Announcement of The Consolidated Financial Report for The 2nd Quarter of 2025
2025.8.5
Provided by: TTY BIOPHARM COMPANY LIMITED
| SEQ_NO | 1 | Date of announcement | 2025/08/05 | Time of announcement | 16:11:22 |
| Subject | Announcement of The Consolidated Financial Report for The 2nd Quarter of 2025 | ||||
| Date of events | 2025/08/05 | To which item it meets | paragraph 31 | ||
| Statement | 1.Date of the board of directors submitted or approved:2025/08/05 2.Date of the audit committee approved:2025/08/05 3.Start and end dates of financial reports or unaudited financial information of the reporting period:2025/01/01~2025/06/30 4.Operating revenue accumulated from 1/1 to end of the period (thousand NTD):2,970,900 5.Gross profit (loss) from operations accumulated from 1/1 to end of the period (thousand NTD):1,771,830 6.Net operating income (loss) accumulated from 1/1 to end of the period (thousand NTD):818,560 7.Profit (loss) before tax accumulated from 1/1 to end of the period (thousand NTD):909,227 8.Profit (loss) accumulated from 1/1 to end of the period (thousand NTD):709,719 9.Profit (loss) during the period attributable to owners of parent accumulated from 1/1 to end of the period (thousand NTD):675,752 10.Basic earnings (loss) per share accumulated from 1/1 to end of the period (NTD):2.72 11.Total assets end of the period (thousand NTD):10,670,265 12.Total liabilities end of the period (thousand NTD):3,744,363 13.Equity attributable to owners of parent end of the period (thousand NTD):6,182,750 14.Any other matters that need to be specified:None. |
||||